Sagimet Updates Pipeline, Reports Phase 3 Acne Trial Underway
Sagimet Biosciences updated its investor presentation, noting an acne Phase 3 trial is underway and planning Phase 2 for TVB-3567. The presentation says funding is expected to support operations through mid-2029.